Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05527652

Self-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia

The researchers are investigating if the Self-Supporting Nasopharyngeal Airway (ssNPA) device can be used in the treatment of obstructive sleep apnea in children with Hypotonic Upper Airway Obstruction (HUAO).

Recruiting

Interested in participating?

Request Info

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children with Hypotonic Upper Airway Obstruction (HUAO): This includes those who newly diagnosed with obstructive sleep apnea (OSA). These children will undergo overnight polysomnography to determine the presence of OSA (apnea-hypopnea index [AHI]>10 or AHI>5 with nocturnal hypoxemia defined as oxygen saturation by pulse oximetry [SpO2] nadir <=75%).
  • All subjects require the presence of at least one symptom of OSA (such as snoring 3 or more nights per week, daytime sleepiness, or hyperactive/inattentive behaviors)
  • Post adenotonsillectomy or those with contraindications to tonsillectomy.
  • Tonsil size 2+ or smaller.
  • Parent/caregivers willing and able to provide informed consent and child willing and able to provide assent, where appropriate.

Exclusion criteria

  • AHI ≤10 on polysomnogram (PSG) without hypoxemia or AHI<5 with hypoxemia.
  • Any medical reason why Self-Supporting Nasopharyngeal Airway (ssNPA) therapy may not be suitable
  • Active Coronavirus (COVID) 19 infections
  • End-tidal carbon dioxide (ETCO2) or Transcutaneous carbon dioxide (TCO2) values >60 mmHg for >10% of sleep time on PSG
  • Psychiatric, medical, or social factors likely to invalidate assessments, make adherence with ssNPA highly unlikely or make local follow-up at 8 weeks unfeasible. Some psychiatric conditions may be provoked or exacerbated by OSA, and those most commonly implicated - Attention Deficit/Hyperactivity Disorder, Conduct Disorder, and Oppositional Defiant Disorder - will not be exclusions. However, more pervasive conditions such as severe autism will be excluded.
  • Presence of supraglottic airway collapse or more distal airway stenosis or collapse (for example glottic, subglottic stenosis, or concern for distal airway stenosis or malacia)
  • Moderate/severe tracheobronchomalacia
  • Need for anticoagulative therapy
  • Bleeding disorder
  • Restrictive thoracic disorders

Treatment and study plan

Self-Supporting Nasopharyngeal Airway (ssNPA)

Device

The ssNPA device is made of a single piece of flexible, medical-grade silicone. It is inserted through one nostril and extends to the anatomic position bypassing the upper airway obstruction above the epiglottis.

Primary outcomes

  1. Apnea-hypopnea index (AHI)

    Time frame: Up to 16 weeks

    Measured during the polysomnogram

  2. Self-Supporting Nasopharyngeal Airway (ssNPA) tolerance

    Time frame: Up to 16 weeks

    Measured by self report. Likert scale 0-5 (higher score is better)

Secondary outcomes

  1. Sleep quality

    Time frame: Up to 16 weeks

    Higher score in parent report of sleep quality on scale 0-5 (higher score is better)

  2. Snoring frequency

    Time frame: Up to 16 weeks

    As reported by participant/care taker in survey given daily. Snoring frequency is rated on a Likert scale 1-5 where 5 indicates snoring more frequently.

  3. Daytime sleepiness

    Time frame: Up to 16 weeks

    Measured using the children's Epworth Sleepiness Scale - The Epworth Sleepiness Scale is a self-administered form with eight items investigating sleep propensity in different real-life situations during the preceding months. Each item can received 0-3 points, thus the final score ranges from 0 (best score) to 24 (worse score).

  4. Quality of life as indicated by the dimensions of the PedsQL (pediatric quality of life) instrument.

    Time frame: Up to 16 weeks

    There are several dimensions of the PedsQL: Physical Functioning, Emotional Functioning, Social Functioning and School Functioning. Each domain will be scored on a scale of 0 (never have problems) to 4 (almost always have problems) and transformed on a scale of 0-100 by reverse scoring (0=100, 1=75, 2=50, 3=25, 4=0). Psychosocial Health Summary Score is the sum of the items over the number of items answered in the Emotional, Social, and School Functioning scales. Physical Health Summary Score is the Physical Functioning Scale Score. The total quality of life score is the sum of all the items over the number of items answered on all scales.

Study contacts

Contact information is provided by the study sponsor or research team.

David A Zopf, MD

CONTACT

[email protected]

608-262-7181

Louise M O'Brien, PhD

CONTACT

[email protected]

734-647-9064

Sponsors and collaborators

Lead sponsor

University of Michigan

Other

Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)
  • National Institutes of Health (NIH)

Registry information

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Sep 2, 2022
Registry last updated
Mar 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.